Search Results - "Xu‐Monette, Z."

Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B‐cell lymphoma patients with and without rheumatic disease by Brauner, S., Zhou, W., Backlin, C., Green, T. M., Folkersen, L., Ivanchenko, M., Löfström, B., Xu‐Monette, Z. Y., Young, K. H., Møller Pedersen, L., Boe Møller, M., Sundström, C., Enblad, G., Baecklund, E., Wahren‐Herlenius, M.

“…Objective TRIM21 (also known as Ro52) is an autoantigen in rheumatic disease and is predominantly expressed in leucocytes. Overexpression is associated with…”
Get full text

Targeting nucleolin for better survival in diffuse large B-cell lymphoma by Jain, N, Zhu, H, Khashab, T, Ye, Q, George, B, Mathur, R, Singh, R K, Berkova, Z, Wise, J F, Braun, F K, Wang, X, Patel, K, Xu-Monette, Z Y, Courty, J, Young, K H, Sehgal, L, Samaniego, F

“…Anthracyclines have been a cornerstone in the cure of diffuse large B-cell lymphoma (DLBCL) and other hematological cancers. The ability of anthracyclines to…”
Get full text

Loss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma by Xia, Y, Xu-Monette, Z Y, Tzankov, A, Li, X, Manyam, G C, Murty, V, Bhagat, G, Zhang, S, Pasqualucci, L, Visco, C, Dybkaer, K, Chiu, A, Orazi, A, Zu, Y, Richards, K L, Hsi, E D, Choi, W W L, van Krieken, J H, Huh, J, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, Winter, J N, Piris, M A, Westin, J, Fowler, N, Miranda, R N, Ok, C Y, Li, Y, Li, J, Medeiros, L J, Young, K H

“…PRDM1 /BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell lymphoma…”
Get full text

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study by Visco, C, Li, Y, Xu-Monette, Z Y, Miranda, R N, Green, T M, Li, Y, Tzankov, A, Wen, W, Liu, W-m, Kahl, B S, d'Amore, E S G, Montes-Moreno, S, Dybkær, K, Chiu, A, Tam, W, Orazi, A, Zu, Y, Bhagat, G, Winter, J N, Wang, H-Y, O'Neill, S, Dunphy, C H, Hsi, E D, Zhao, X F, Go, R S, Choi, W W L, Zhou, F, Czader, M, Tong, J, Zhao, X, van Krieken, J H, Huang, Q, Ai, W, Etzell, J, Ponzoni, M, Ferreri, A J M, Piris, M A, Møller, M B, Bueso-Ramos, C E, Medeiros, L J, Wu, L, Young, K H

“…Gene expression profiling (GEP) has stratified diffuse large B-cell lymphoma (DLBCL) into molecular subgroups that correspond to different stages of lymphocyte…”
Get full text

E3 ubiquitin ligase TRIM32 negatively regulates tumor suppressor p53 to promote tumorigenesis by Liu, Ju, Zhang, C, Wang, X L, Ly, P, Belyi, V, Xu-Monette, Z Y, Young, K H, Hu, W, Feng, Z

“…Tumor suppressor p53 has a key role in maintaining genomic stability and preventing tumorigenesis through its regulation of cellular stress responses,…”
Get full text

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy by Yao, Z, Deng, L, Xu-Monette, Z Y, Manyam, G C, Jain, P, Tzankov, A, Visco, C, Bhagat, G, Wang, J, Dybkaer, K, Tam, W, Hsi, E D, van Krieken, J H, Ponzoni, M, Ferreri, A J M, Møller, M B, Winter, J N, Piris, M A, Fayad, L, Liu, Y, Song, Y, Orlowski, R Z, Kantarjian, H, Medeiros, L J, Li, Y, Cortes, J, Young, K H

“…In diffuse large B-cell lymphoma (DLBCL), the clinical and biological significance of concordant and discordant bone marrow (BM) involvement have not been well…”
Get full text

Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium by Deng, L, Xu-Monette, Z Y, Loghavi, S, Manyam, G C, Xia, Y, Visco, C, Huh, J, Zhang, L, Zhai, Q, Wang, Y, Qiu, L, Dybkær, K, Chiu, A, Perry, A M, Zhang, S, Tzankov, A, Rao, H, Abramson, J, Sohani, A R, Xu, M, Hsi, E D, Zhu, J, Ponzoni, M, Wang, S, Li, Ling, Zhang, M, Ferreri, A J M, Parsons, B M, Li, Y, Piris, M A, Medeiros, L J, Young, K H

“…Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a unique subtype of DLBCL. The impact of rituximab on survival and patterns of treatment failure…”
Get full text

LYMFOREST‐25 : PERSONALLY‐TAILORED SURVIVAL PREDICTION OF PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA USING CLINICO‐GENOMIC PROGNOSTIC MODELS by Orgueira, A. Mosquera, López, M. Cid, Raindo, A. Peleteiro, Díaz Arias, J. Án., Pérez, M. S. González, Rodríguez, B. Antelo, Pérez, L. Bao, Ferro, R. Ferreiro, Santos, C. Aliste, Encinas, M. M. Pérez, Rodríguez, M. F. Fraga, Xu‐Monette, Z., Visco, C., Young, K., López, J. L. Bello

Get full text

Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma by Frei, E, Visco, C, Xu-Monette, Z Y, Dirnhofer, S, Dybkær, K, Orazi, A, Bhagat, G, Hsi, E D, van Krieken, J H, Ponzoni, M, Go, R S, Piris, M A, Møller, M B, Young, K H, Tzankov, A

“…High levels of cyclin E (CCNE) are accompanied by shorter survival in cyclophosphamide, hydroxydaunorubicin, oncovin and prednisone (CHOP)-treated diffuse…”
Get more information

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study by Visco, C, Li, Y, Xu-Monette, Z.Y, Miranda, R.N, Green, T.M, Tzankov, A, Wen, W, Liu, W-m, Kahl, B.S, d'Amore, E.S.G, Montes-Moreno, S, Dybkaer, K, Chiu, A, Tam, W, Orazi, A, Zu, Y, Bhagat, G, Winter, J.N, Wang, H.-Y, O'Neill, S, Dunphy, C.H, Hsi, E.D, Zhao, X.F, Go, R.S, Choi, W.W.L, Zhou, F, Czader, M, Tong, J, Zhao, X, van Krieken, J.H, Huang, Q, Ai, W, Etzell, J, Ponzoni, M, Ferreri, A.J.M, Piris, M.A, Moller, M.B, Bueso-Ramos, C.E, Medeiros, L.J, Wu, L, Young, K.H

Get full text

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study by Visco, Carlo, Tzankov, Alexander, Xu-Monette, Zijun Y, Miranda, Roberto N, Tai, Yu Chuan, Li, Yan, Liu, Wei-min, d'Amore, Emanuele S G, Li, Yong, Montes-Moreno, Santiago, Dybkær, Karen, Chiu, April, Orazi, Attilio, Zu, Youli, Bhagat, Govind, Wang, Huan-You, Dunphy, Cherie H, His, Eric D, Zhao, X Frank, Choi, William W L, Zhao, Xiaoying, van Krieken, J Han, Huang, Qin, Ai, Weiyun, O'Neill, Stacey, Ponzoni, Maurilio, Ferreri, Andres J M, Kahl, Brad S, Winter, Jane N, Go, Ronald S, Dirnhofer, Stephan, Piris, Miguel A, Møller, Michael B, Wu, Lin, Medeiros, L Jeffrey, Young, Ken H

“…Diffuse large B-cell lymphoma can be classified by gene expression profiling into germinal center and activated B-cell subtypes with different prognoses after…”
Get full text

Reduced expression of TRIM 21/Ro52 predicts poor prognosis in diffuse large B‐cell lymphoma patients with and without rheumatic disease by Brauner, S., Zhou, W., Backlin, C., Green, T. M., Folkersen, L., Ivanchenko, M., Löfström, B., Xu‐Monette, Z. Y., Young, K. H., Møller Pedersen, L., Boe Møller, M., Sundström, C., Enblad, G., Baecklund, E., Wahren‐Herlenius, M.

Get full text

PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program by Li, Ling, Sun, Ruifang, Miao, Yi, Tran, Thai, Adams, Lisa, Roscoe, Nathan, Xu, Bing, Manyam, Ganiraju C., Tan, Xiaohong, Zhang, Hongwei, Xiao, Min, Tzankov, Alexandar, Visco, Carlo, Dybkaer, Karen, Bhagat, Govind, Tam, Wayne, Hsi, Eric D., van Krieken, J. Han, You, Hua, Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J. M., Møller, Michael B., Piris, Miguel A., Zhang, Mingzhi, Winter, Jane N., Medeiros, L. Jeffrey, Rassidakis, George Z., Vaupel, Christine A., Li, Yong, Dakappagari, Naveen, Xu-Monette, Zijun Y., Young, Ken H.

“…Programmed cell death protein 1/programmed cell death protein ligand1 (PD-1/PD-L1) interaction is an important immune checkpoint targeted by anti-PD-1/PD-L1…”
Get full text

Erratum: Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study by Visco, C, Li, Y, Xu-Monette, Z Y, Miranda, R N, Green, T M, Tzankov, A, Wen, W, Liu, W-m, Kahl, B S, d'Amore, E S G, Montes-Moreno, S, Dybkær, K, Chiu, A, Tam, W, Orazi, A, Zu, Y, Bhagat, G, Winter, J N, Wang, H-Y, O'Neill, S, Dunphy, C H, Hsi, E D, Zhao, X F, Go, R S, Choi, W W L, Zhou, F, Czader, M, Tong, J, Zhao, X, van Krieken, J H, Huang, Q, Ai, W, Etzell, J, Ponzoni, M, Ferreri, A J M, Piris, M A, Møller, M B, Bueso-Ramos, C E, Medeiros, L J, Wu, L, Young, K H

“…Correction to: Leukemia (2012) 26, 2103–2113; doi:10.1038/leu.2012.83 Since the publication of this article, the authors have identified an omission in their…”
Get full text

Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: Implications in the etiology of multiple myeloma by Gordon, Michael W., Yan, Fang, Zhong, Xiaoming, Mazumder, Pranab Behari, Xu-Monette, Zijun Y., Zou, Dehui, Young, Ken H., Ramos, Kenneth S., Li, Yong

“…Multiple myeloma (MM) is a common and deadly cancer of blood plasma cells. A unique feature of MM is the extremely low somatic mutation rate of the p53 tumor…”
Get full text

PD-L1 Expression and Gene Amplification in CD30+ Diffuse Large B-Cell Lymphoma (DLBCL): Significance of TP53 Genetic Impact and Clinicopathologic Characteristics by Rassidakis, George, Miao, Yi, Zhang, Jun, Atsaves, Vassilis, Kis, Lorand, Smedby, Karin E, Li, Yong, Xu-Monette, Zijun Yidan, Young, Ken H.

“…Introduction: Regulation of the PD-1/PD-L1 immune checkpoint has been under intense investigation in the era of immunotherapy, and PD-1 blocκade has shown…”
Get full text

Clinical Significance of PD-1 and PD-L1 Expression and Ongoing Interaction in the Tumor Microenvironment in Diffuse Large B Cell Lymphoma (DLBCL) Treated with R-CHOP by Xu-Monette, Zijun Yidan, Yu, Li, Tran, Thai, Adams, Lisa, Roscoe, Nathan, Manyam, Ganiraju, Visco, Carlo, Tzankov, Alexandar, Dybkær, Karen, Bhagat, Govind, Chiu, April, Tam, Wayne, Zu, Youli, Hsi, Eric D., Van Krieken, Joannes H.J.M., Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andres, Møller, Michael Boe, Piris, Miguel Angel, Winter, Jane N., Medeiros, L. Jeffrey, Rassidakis, George, Vaupel, Christine Angela, Li, Yong, Dakappagari, Naveen, Young, Ken H.

“…Background: PD-1 blockade has demonstrated antitumor activity in diffuse large B-cell lymphoma (DLBCL). In order to select patients who are more likely to…”
Get full text

ETS1 PHOSPHORYLATION AT THR38 (PETS1) IS ASSOCIATED WITH CELL OF ORIGIN (COO), CELL CYCLE ACTIVATION, AND INFERIOR OUTCOME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) by Chung, E.Y., Ponzoni, M., Xu‐Monette, Z.Y., Cascione, L., Priebe, V., Gaudio, E., Wang, J., Zhang, J., Visco, C., Bhagat, G., Zucca, E., Rossi, D., Young, K.H., Bertoni, F.

Get full text